Executives from Cytori Therapeutics Inc., Orthofix International NV, Viacell Inc., Geron Corp., Osiris Therapeutics Inc. are among those slated to present at the second annual "Stem Cell Summit," a conference focusing on the commercialization of stem cell products starting Monday in San Diego.
Cytori Therapeutics Chief Executive Chris Calhoun will outline the company's commercialization strategy for its breast reconstruction product and provide an update on the start of a cardiovascular disease clinical trial.
Orthofix International subsidiary Blackstone Medical Inc.'s director of research and education, Raymond J. Linovitz, will give a presentation discussing the potential that adult stem cells provide for the orthopedic industry.
ViaCell Chief Technology Officer Morey Kraus is slated to discuss the company's work using cord blood stem cells in cancer treatment. Jane Lebkowski of Geron Corp. is on the agenda to discuss embryonic stem cell technology and transplants, and Osiris President and Chief Executive C. Randal Mills will discuss their work on orthopedic and cardiovascular uses for stem cell therapies.
Researchers hope they can train human embryonic stem cells to repair damaged organs in need of healthy cells, but the Bush administration has restricted federal funding for embryo work since 2001, leading some scientists to seek alternative sources for stem cells.
States have also stepped in to fill in funding gaps for embryonic stem cell research. New Jersey agreed in December to spend millions of dollars on the research, joining California, Connecticut, Illinois and Maryland in providing state funds in the field. Other states are considering similar moves.
CYTORI THERAPEUTICS (NasdaqGM:CYTX) is trading up today 52 cents to $6.32 per share.
ORTHOFIX INTL NV (NasdaqGS:OFIX) is trading down now, 54 cents per share at 49.46.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment